ENIGMA-Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes
Open Access
- 11 October 2011
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 33 (1), 2-7
- https://doi.org/10.1002/humu.21628
Abstract
As genetic testing for predisposition to human diseases has become an increasingly common practice in medicine, the need for clear interpretation of the test results is apparent. However, for many disease genes, including the breast cancer susceptibility genes BRCA1 and BRCA2, a significant fraction of tests results in the detection of a genetic variant for which disease association is not known. The finding of an “unclassified” variant (UV)/variant of uncertain significance (VUS) complicates genetic test reporting and counseling. As these variants are individually rare, a large collaboration of researchers and clinicians will facilitate studies to assess their association with cancer predisposition. It was with this in mind that the ENIGMA consortium (www.enigmaconsortium.org) was initiated in 2009. The membership is both international and interdisciplinary, and currently includes more than 100 research scientists and clinicians from 19 countries. Within ENIGMA, there are presently six working groups focused on the following topics: analysis, clinical, database, functional, tumor histopathology, and mRNA splicing. ENIGMA provides a mechanism to pool resources, exchange methods and data, and coordinately develop and apply algorithms for classification of variants in BRCA1 and BRCA2. It is envisaged that the research and clinical application of models developed by ENIGMA will be relevant to the interpretation of sequence variants in other disease genes. Hum Mutat 33:2–7, 2012.Keywords
This publication has 28 references indexed in Scilit:
- Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variantsHuman Mutation, 2011
- Prediction and assessment of splicing alterations: implications for clinical testingHuman Mutation, 2008
- Genetic evidence and integration of various data sources for classifying uncertain variants into a single modelHuman Mutation, 2008
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- Functional Assays for Classification ofBRCA2Variants of Uncertain SignificanceCancer Research, 2008
- Clinical Classification ofBRCA1andBRCA2DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the kConFab InvestigatorsJournal of Clinical Oncology, 2008
- A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition GenesAmerican Journal of Human Genetics, 2007
- Classification of missense variants of unknown significance inBRCA1based on clinical and tumor informationHuman Mutation, 2007
- Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical SignificanceCancer Research, 2006
- Integrated Evaluation of DNA Sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2American Journal of Human Genetics, 2004